Kala Pharma Has 2 Material Milestones Upcoming In Q4

Biotech traders are always on the lookout for stocks with major catalysts on the horizon, and newly-public Kala Pharmaceuticals Inc KALA fits the mold ahead of what will be a critical second half of 2017 for the company.

On Monday, Wedbush analyst Liana Moussatos highlighted two key catalysts coming up for Kala investors that could have major implications for the stock.

By the end of the year, Kala will likely deliver an NDA submission for its eye drop treatment of post-op inflammation and pain. In addition, the company will also likely complete both of its ongoing Phase III trials for dry eye disease flares.

“Both ocular conditions have been somewhat derisked and with material catalysts anticipated in Q4:17, blockbuster sales potential for dry eye over $1 billion, acquisition potential and an attractive valuation, we anticipate KALA is likely to OUTPERFORM in 2017,” she wrote.

Related Link: This Biotech Name Could Be Best In Breed For 2017

Wedbush projects 2027 gross annual sales for Kala lead drug candidate KPI-121 1% at $271 million for post-op inflammation and 2027 sales of KPI-121 0.25% for dry eye disease flares at $1.9 billion.

The firm expects positive developments in the second half of 2017 will ultimately drive the stock to a price target of $46, more than double its current share price.

Sell-Side Weighs In

Wedbush isn’t the only Wall Street firm bullish on Kala. Wells Fargo analyst Davis Maris also initiated coverage of Kala at Outperform on Monday but is much less bullish on the near-term upside.

“We believe that Kala offers a differentiated opportunity in the growing eye disease market, with two promising programs in its pipeline,” Maris wrote.

Wells Fargo’s target of $24 represents only about 14 percent upside from Kala’s current share price. JPMorgan also initiated coverage on Kala on Monday with an Overweight rating and $35 price target.

Posted In: Davis MarisLiana MoussatosWedbushWells FargoAnalyst ColorBiotechLong IdeasPrice TargetInitiationAnalyst RatingsTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.